Drugs / GB-102
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03249740 | Aug 2017 → Sep 2018 | wet macular degeneration | Graybug Vision | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03953079 | Sep 2019 → Dec 2020 | wet macular degeneration | Graybug Vision | Completed | No outcome recorded |
| Phase 2 | NCT04085341 | Sep 2019 → Jun 2020 | diabetic macular edema, retinal vein occlusion | Graybug Vision | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03249740 ↗ |
| Route | Intravitreal | “Intravitreal injection of GB-102” NCT03249740 ↗ |